Exploring genetic variants of human PKR against the pseudosubstrate antagonist vaccinia K3.
(A) (Left) AlphaFold2 model of the PKR kinase domain (green) bound to its target, eIF2α (gray). (Right) Rotated 90°, the eIF2α binding surface of PKR is shaded gray and outlined in white dashed line. (B) AlphaFold2 model of the PKR kinase domain bound to vaccinia K3 (purple). Rotated 90°, the K3 binding surface of PKR is shaded purple and outlined in black dashed line. (C) PKR kinase domain with vertebrate positive selection sites highlighted in red (22), with the K3 binding surface delineated with dashed line. (D) (Left) The PKR kinase domain with four windows highlighted in which we designed 426 nonsynonymous variants. Secondary structures occurring in these windows (alpha helices α0, αD, and αG, beta strand β1, and the kinase activation loop) are marked (5). The positions of conserved sites and sites under positive selection (22) are denoted above with black and red triangles, respectively, and the positions of sites within 5 angstroms of either K3 or eIF2α in an Alphafold2 binding model are denoted with purple and gray triangles, respectively. (Right) Mutated windows are highlighted on the surface of the PKR kinase domain, with the K3 binding surface delineated with dashed line, and in cartoon form with secondary structures marked. (E) Methodological approach to explore the effects of variants of human PKR in the presence of different K3 alleles. 426 nonsynonymous variants of PKR were generated and paired with wild-type K3, K3Δ58, and K3-H47R. Variant effects were characterized using a high-throughput yeast growth assay and massively parallel sequencing.